Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
Status:
Recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of the combination of olaparib, durvalumab, and fulvestrant
for the treatment of patients with ER-positive, HER2-negative, locally advanced or metastatic
breast cancer with BRCA gene alterations or alterations of genes involved in homologous
recombination repair (HRR) or microsatellite instability (MSI) status.
Phase:
Phase 2
Details
Lead Sponsor:
UNICANCER
Collaborators:
ARCAGY- GYNECO ARCAGY/ GINECO GROUP SOLTI Breast Cancer Research Group